Skip to main content
. 2021 Apr 15;22(8):4098. doi: 10.3390/ijms22084098

Figure 2.

Figure 2

Loss of NEIL3 facilitates docetaxel resistance of DU145 and PC3 but does not affect androgen deprivation therapy (ADT) resistance. (A–D) qRT-PCR and western blot analysis for NEIL3 expression in NEIL3 knockdown LNcap, DU145 and PC3 cells. (E) The MTS assay to determine IC50 of enzalutamide in LNcap cells after treatment. (F,G) The MTS assay to determine IC50 of docetaxel in DU145 and PC3 cells after treatment, * p < 0.05, ** p < 0.01 and *** p < 0.001, versus corresponding control group.